BioSpecifics Technologies

BioSpecifics Technologies Corp. is a biopharmaceutical company primarily engaged in the development of injectable collagenase for various indications in the United States. It provides Xiaflex injectable collagenase for the treatment of Dupuytren's contracture and Peyronie’s disease. The company is also developing Xiaflex injectable collagenase for other indications including frozen shoulder, cellulite, human lipoma, canine lipoma, uterine fibroids, as well as adjuvant indications such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated discs, and vitrectomy. The company was founded in 1957 and is headquartered in Lynbrook, New York.